This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Enalapril in Collagen Type 4 Nephropathy

This study has been completed.
Information provided by (Responsible Party):
Maria Helena Vaisbich, University of Sao Paulo Identifier:
First received: October 27, 2011
Last updated: November 1, 2011
Last verified: November 2011
Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function. In humans there is no proven treatment. Methods: This is a retrospective study of patients with Collagen IV-related nephropathies and proteinuria treated with enalapril analyzing the evolution of proteinuria and renal function, as well as predictive variables of progression to end stage renal disease. Outcome was creatinine clearance < 60 ml/min/1.73m2.

Collagen Type-4 Nephropathies

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Collagen Type 4-related Nephropathies: From Alport to Thin Membrane Nephropathy. A Series of Cases Treated With Angiotensin Converting Enzyme Inhibitor

Resource links provided by NLM:

Further study details as provided by Maria Helena Vaisbich, University of Sao Paulo:

Primary Outcome Measures:
  • proteinuria [ Time Frame: two years ]
    evaluate the proteinuria during two years of treatment with enalapril

Secondary Outcome Measures:
  • evaluate the creatinine clearance during treatment with enalapril [ Time Frame: two years ]

Enrollment: 19
Study Start Date: January 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Collagen type 4 nephropathies and proteinuria followed in Pediatric Nephrology Unit of Instituto da Criança - HCFMUSP

Inclusion Criteria:

  • age under 18 years old
  • non-adherent to the exams and evaluations

Exclusion Criteria:

  • creatinine clearance < 60 ml/minute/1.73m2BS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Maria Helena Vaisbich, Principal Investigator, University of Sao Paulo Identifier: NCT01465126     History of Changes
Other Study ID Numbers: Registry Identifier
Study First Received: October 27, 2011
Last Updated: November 1, 2011

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017